Trials / Recruiting
RecruitingNCT06235242
GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT201 injection in combination with teraplizumab injection | GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer |
Timeline
- Start date
- 2024-02-02
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2024-01-31
- Last updated
- 2025-02-07
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06235242. Inclusion in this directory is not an endorsement.